Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: Biogen Idec

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

4Q Revenues: $633 million (+8%)

4Q Earnings: $56 million (+94%)

FY Revenues: $2.4 billion (+10%)

FY Earnings: $161 million (+541%)

Comments: Revenues for the quarter and full year were driven by Rituxan and Avonex. Rituxan revenues were up 15% to $709 million and Avonex sales were up 9% to $1.5 billion for the year. Rituxan revenues were up 6% to $182 million and Avonex sales were up 12% to $413 million for the quarter. Revenues for the quarter and full year included $182 million and $709 million, respectively, from Biogen Idec’s joint business arrangement with Genentech, related to Rituxan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters